Effect of prednisone on transforming growth factor-β1, connective tissue growth factor, nuclear factor-κBp65 and tumor necrosis factor-α expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum

Hepatology Research

Volumn 41, Issue 8, 2011, Pages 795-803

  Zhu, Hongyi ^a   Chu, Yi ^a   Huo, Jirong ^a   Chen, Zhe ^a   Yang, Li ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Connective tissue growth factor; Gynura segetum; Hepatic sinusoidal obstruction syndrome; Prednisone; Transforming growth factor 1

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EOSIN; HEMATOXYLIN; MESSENGER RNA; PREDNISONE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GYNURA SEGETUM; HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME; HERB; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER SLICE; LIVER VEIN OBSTRUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; WESTERN BLOTTING;

EID: 79960725915     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00830.x     Document Type: Article

References (40)

1. Bras G, Jelliffe DB, Stuart KL. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. AMA Arch Pathol 1954; 57: 285-300.
2. Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 2006; 23 (1): 11-25.
3. Fu PP, Xia Q, Lin G etal. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004; 36: 1-55.
4. Al Beihany A, Al Omar H, Sahovic E etal. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 2008; 41: 287-91.
5. Akyuz C, CaClar K, Emir S etal. High-dose methylprednisolone treatment of hepatic veno-occlusive disease in a child with Wilms tumor. Pediatr Hematol Oncol 2003; 20: 345-9.
6. Sayer HG, Will U, Schilling K etal. Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation- successful treatment with high-dose methylprednisolone and defibrotide. J Cancer Res Clin Oncol 2002; 128: 148-52.
7. Khoury H, Adkins D, Brown R etal. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant 2000; 25: 737-43.
8. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
9. Pihusch V, Pihusch M, Penovici M etal. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res 2005; 116: 233-40.
10. Rachfal AW, Brigstock DR. Structural and functional properties of CCN proteins. Vitam Horm 2005; 70: 69-103.
11. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006; 27: 715-23.
12. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res 1999; 23: 911-16.
13. Bissell DM, Friedman SL, Maher JJ etal. Connective tissue biology and hepatic fibrosis: report of a conference. Hepatology 1990; 11: 488-98.
14. Hideshima T, Chauhan D, Richardson P etal. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.
15. Saile B, Matthes N, El Armouche H etal. The bcl, NF kappa B and p53/p21(WAF1) systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol 2001; 80: 554-61.
16. DeLeve LD, McCuskey RS, Wang X etal. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29: 1779-91.
17. Chen MY, Cai JT, Du Q etal. Reliable experimental model of hepatic veno-occlusive disease caused by monocrotaline. Hepatobiliary Pancreat Dis Int 2008; 7: 395-400.
18. Chen M, Cai J, Du Q. Hepatic veno-occlusive disease associated with the use of Gynura segetum. Eur J Intern Med 2007; 18: 609.
19. Ma X. Sonogaphic characteristics of hepatic veno-occlusive disease. Zhejiang Clin Med J 2008; 5: 593-4.
20. Liu J, Pu X, Wu Y. Clinical and pathological diagnosis of hepatic veno-occlusive disease. J Clin Hepatol 2008; 2: 107-9.
21. Zhang M, Shi H, Zhang Y. Treatment of hepatic veno-occlusive disease induced by overdose of Gynura segetum. Zhejiang J Traumatic Surg 2009; 1: 90.
22. Huang J. Treatment of 8 cases of hepatic veno-occlusive disease induced by Tusanqi. Mod J Integr Tradit Chin West Med 2009; 4: 412.
23. Huang H, Liu Y, Lin J etal. The diagnosis and treatment of hepatic veno-occlusive disease induced by Gynura root. Chin J Clin Gastroenterol 2008; 1: 26-28+32.
24. Li S, Yang L, Xiong L etal. A case report of wrong diagnosis of hepatic veno-occlusive disease and review of the literature. Chin J Integr Tradit West Med Liver Dis 2007; 4: 251-2.
25. Li J, Hu M, Jin H etal. Treatment of hepatic veno-occlusive disease by orthotopic liver transplantation. Chin J Hepatobiliary Surg 2001; 6: 1.
26. Li Y, Du N, Wang F etal. Two cases of hepatic veno-occlusive disease induced by Tusanqi. Chin J Clin Hepatol 2006; 4: 319-20.
27. Fang L, Fan Y, Wang X etal. Two cases of veno-occlusive disease and review. Chin J Gastroenterol Hepatol 2008; 6: 513-16.
28. Chen W, Yang M, Yu Z etal. Two cases of hepatic veno-occlusive disease induced by Tusanqi. Chin J Hepatol 2005; 5: 394-5.
29. Yan H, Bai L, Peng M. A case report of acute liver damage induced by Jusanqi. Mod Digestion Interv 2006; 4: 258.
30. Dai N, Yu YC, Ren TH etal. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol 2007; 13: 1628-31.
31. Han EH, Hu XJ. Two cases of hepatic veno-occlusive disease induced by vincristine. Chin J Clin (Electronic Edition) 2010; 3: 352-3.
32. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22 (1): 27-42.
33. Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999; 107: 485-93.
34. Morabito F, Gentile M, Gay F etal. Insights into defibrotide: an updated review. Expert Opin Biol Ther 2009; 9: 763-72.
35. Yang L, Zhu HY, Chen Z etal. Comparison of the hepatic veno-occlusive disease models induced by gynura segetum, monocrotaline and cyclophosphamide. Chin J Hepatol 2010; 18: 944-5.
36. Ding N, Li Y. Expression of transforming growth factor-β1 and connective tissue growth factor in hepatic fibrosis. World Chin J Digestol 2006; 25: 2521-6.
37. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
38. Hellerbrand C, Jobin C, Iimuro Y etal. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 1998; 27: 1285-95.
39. Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp Mol Pathol 2001; 71: 226-40.
40. Hideshima T, Chauhan D, Richardson P etal. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.